
Opinion|Videos|August 1, 2024
Emerging Agents in IPF Treatment
Author(s)Steven D. Nathan, MD
Steven Nathan, MD, discusses breakthrough treatments for idiopathic pulmonary fibrosis.
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following:
- There are several agents with new mechanisms of action in the pipeline for idiopathic pulmonary fibrosis (IPF). Which are you most excited about? What is the potential impact these agents, if approved, could have on the IPF treatment landscape?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis
2
Pulling Back Funding for Research COuld Leave HIV Treatment in Worse State: Patrick Sullivan, DVM, PhD
3
Value-Based Care Interventions and Management of CKD Progression
4
HMA Combination Therapy Boosts Survival in Accelerated- or Blast-Phase MPNs
5